Antiviral Probes

1 Valacyclovir and Valganciclovir

Valacyclovir inhibits EBV/VZV/HSV DNA polymerase. Valganciclovir has broader coverage (HHV-6, CMV) and greater potency, but carries a Black Box Warning for bone marrow suppression and is Category C (energy-demanding). Both probe whether active herpesvirus replication contributes to ongoing symptoms.

1.1 If antivirals work

Finding: Active herpesvirus replication was contributing.

Drug blocked viral DNA polymerase → viral replication suppressed → symptoms improved over months → viral activity was driving symptoms.

Certainty: Medium for valacyclovir (Lerner 36-month placebo-controlled trial, ~30–40% response (Lerner et al. 2007)). Medium for valganciclovir (Montoya EVOLVE RCT, n=30, 50–60% response (Montoya et al. 2013)). Both single-group, not independently replicated.
Does NOT tell us: whether the virus is root cause or secondary reactivation enabled by immune dysfunction. Relapse on discontinuation suggests suppression, not cure.
Level of action: Partial root cause — antivirals suppress the viral amplifier without correcting the immune deficit that permitted reactivation.

Finding: HHV-6 or CMV was specifically involved.

Valacyclovir’s limited spectrum failed; valganciclovir’s broader coverage succeeded.

Certainty: Medium — differential spectrum is established pharmacology.
Level of action: Partial root cause.

Finding: Immune function was sufficient to sustain antiviral benefit.

If improvement persists after discontinuation, the immune system controls residual virus once the replication burden was reduced.

Certainty: Low — anecdotally documented, not systematically quantified.
Level of action

1.2 What a positive response does NOT reveal

A positive antiviral response confirms that active herpesvirus replication was contributing but does not reveal whether the virus is the root cause or a secondary reactivation enabled by an underlying immune deficit. Relapse on discontinuation points to suppression rather than cure. It does not, by itself, identify which virus is responsible unless a differential spectrum trial is run (valacyclovir failure followed by valganciclovir success implicates HHV-6 or CMV). Because both antiviral trials are single-group and not independently replicated, an individual response cannot be cleanly separated from placebo or natural fluctuation.

1.3 If antivirals do NOT work

Active viral replication not the dominant disease driver — elevated antibody titers may reflect immune memory, not active infection.
Virus in sanctuary site the drug cannot reach — CNS, salivary glands, latent reservoirs.
Viral reactivation is a consequence, not cause — blocking virus without correcting immune deficit simply shunts virus into a different latency program.
Incorrect patient selection — elevated antibody titers (>90% EBV seropositive in general population) without confirmatory markers (EA-D, PCR) → low pretest probability.

1.4 Key caveat

Non-response does not exclude a viral contribution. The drug may fail to reach virus sequestered in sanctuary sites (CNS, salivary glands, latent reservoirs), or the reactivation may be a consequence of an uncorrected immune deficit rather than a cause — blocking polymerase without correcting immunity can simply shunt the virus into a different latency program. Non-response is weaker evidence than response: it makes active replication less likely to be dominant but does not rule it out. For the limits of what an antiviral null can conclude about viral origin specifically — including the trigger vs. amplifier vs. ongoing-driver distinction — see What Pharmacodiagnostics Can and Cannot Rule Out: Origin Hypotheses.

1.5 How Valacyclovir and Valganciclovir combine with other medications

Valacyclovir works + LDN works → two independent drivers: virus + neuroinflammation.
Valacyclovir failure + valganciclovir success → HHV-6 or CMV involvement.
Valacyclovir works + relapse on discontinuation → viral suppression, not cure; immune deficit persists.
Valacyclovir does not work + cimetidine works → viral component may respond to immune enhancement rather than direct polymerase inhibition.

1.6 Compendium

The full pharmacodiagnostic entries — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — are at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Valacyclovir entry and Valganciclovir entry).

References

Lerner, A Martin, Safedin H Beqaj, Robert G Deeter, and James T Fitzgerald. 2007. “Valacyclovir Treatment in Epstein-Barr Virus Subset Chronic Fatigue Syndrome: Thirty-Six Months Follow-up.” In Vivo 21 (5): 707–13. https://pubmed.ncbi.nlm.nih.gov/18019402/.

Montoya, Jose G, Andreas M Kogelnik, Munveer Bhangoo, Mitchell R Lunn, Louis Flamand, Lindsey E Merrihew, Tessa Watt, Jessica T Kubo, Jane Paik, and Manisha Desai. 2013. “Randomized Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir in a Subset of Patients with Chronic Fatigue Syndrome.” Journal of Medical Virology 85 (12): 2101–9. https://doi.org/10.1002/jmv.23713.